OBJECTIVES: Vitiligo is an autoimmune disease that causes depigmentation of the skin and significantly impacts the quality of life of patients. In Colombia, the National Registry of Patients with Vitiligo (REVIC) is focused on collecting real-world data about this disease in our country. Our aim was to describe the clinical and sociodemographic characteristics of patients with vitiligo, as well as the treatment patterns in Colombia.

METHODS: We conducted a descriptive study that included patients diagnosed with vitiligo, receiving a minimum of four months of treatment, and diagnosed since 2013 at dermatological offices or centers in Bogota, Cartagena, and Valledupar cities. Data were collected from medical records between December 2023 and January 2024. Descriptive statistics are reported.

RESULTS: A total of 277 patients were included, with 57.4% being women and 49.5% residing in urban areas. The median age was 40 years [IQR: 24-56]; 246 patients (88.8%) were over 18 years old, and 63% had onset of symptoms before 40 years. The majority of patients had generalized vitiligo (46.2%), followed by focal vitiligo (33.9%). The most commonly used treatments were topical calcineurin inhibitor (59.2%), topical steroids (43.7%) and phototherapy (31.1%). No patients received surgical treatment or excimer laser. Dermatological comorbidities were reported in 6.5% of patients and 11% had thyroid comorbidities.

CONCLUSIONS: Vitiligo was more frequent among women and the adult population. The majority of patients had generalized vitiligo. Notably, topical calcineurin inhibitor and topical steroids were the predominant treatments.